Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers

Shibo Fu, Ying Yang, Das Tirtha, Yun Yen, Bing sen Zhou, Ming Ming Zhou, Michael Ohlmeyer, Eric C. Ko, Ross Cagan, Barry S. Rosenstein, Shu hsia Chen, Johnny Kao

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. Methods: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. Results: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. Conclusions: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.

Original languageEnglish
Article numbere38465
JournalPLoS One
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 29 2012
Externally publishedYes

Fingerprint

ribonucleotide reductase
Ribonucleotide Reductases
Assays
Screening
Ionizing radiation
Cells
Ionizing Radiation
screening
ionizing radiation
kinetics
Molecules
Kinetics
assays
Small Molecule Libraries
Drug therapy
Double-Stranded DNA Breaks
DNA
Radiotherapy
immunocytochemistry
prostatic neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers. / Fu, Shibo; Yang, Ying; Tirtha, Das; Yen, Yun; Zhou, Bing sen; Zhou, Ming Ming; Ohlmeyer, Michael; Ko, Eric C.; Cagan, Ross; Rosenstein, Barry S.; Chen, Shu hsia; Kao, Johnny.

In: PLoS One, Vol. 7, No. 6, e38465, 29.06.2012.

Research output: Contribution to journalArticle

Fu, S, Yang, Y, Tirtha, D, Yen, Y, Zhou, BS, Zhou, MM, Ohlmeyer, M, Ko, EC, Cagan, R, Rosenstein, BS, Chen, SH & Kao, J 2012, 'Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers', PLoS One, vol. 7, no. 6, e38465. https://doi.org/10.1371/journal.pone.0038465
Fu, Shibo ; Yang, Ying ; Tirtha, Das ; Yen, Yun ; Zhou, Bing sen ; Zhou, Ming Ming ; Ohlmeyer, Michael ; Ko, Eric C. ; Cagan, Ross ; Rosenstein, Barry S. ; Chen, Shu hsia ; Kao, Johnny. / Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers. In: PLoS One. 2012 ; Vol. 7, No. 6.
@article{61123865e31f47ae879fd2dff4c5339c,
title = "Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers",
abstract = "Background: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. Methods: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. Results: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. Conclusions: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.",
author = "Shibo Fu and Ying Yang and Das Tirtha and Yun Yen and Zhou, {Bing sen} and Zhou, {Ming Ming} and Michael Ohlmeyer and Ko, {Eric C.} and Ross Cagan and Rosenstein, {Barry S.} and Chen, {Shu hsia} and Johnny Kao",
year = "2012",
month = "6",
day = "29",
doi = "10.1371/journal.pone.0038465",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers

AU - Fu, Shibo

AU - Yang, Ying

AU - Tirtha, Das

AU - Yen, Yun

AU - Zhou, Bing sen

AU - Zhou, Ming Ming

AU - Ohlmeyer, Michael

AU - Ko, Eric C.

AU - Cagan, Ross

AU - Rosenstein, Barry S.

AU - Chen, Shu hsia

AU - Kao, Johnny

PY - 2012/6/29

Y1 - 2012/6/29

N2 - Background: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. Methods: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. Results: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. Conclusions: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.

AB - Background: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. Methods: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. Results: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. Conclusions: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.

UR - http://www.scopus.com/inward/record.url?scp=84863084904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863084904&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0038465

DO - 10.1371/journal.pone.0038465

M3 - Article

C2 - 22768044

AN - SCOPUS:84863084904

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e38465

ER -